Clinical trial
Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
NCT04919109 is registered in ClinicalTrials.gov with Codagenix, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
- Lead sponsor
- Codagenix, Inc
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- March 28, 2023
- Completion date
- July 8, 2026
- Enrollment
- 41 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.